DDInter1379 DDInter1376
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Palbociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Palbociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Escitalopram
Palbociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Palbociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sufentanil
Palbociclib {u} may lead to a major life threatening interaction when taken with {v} Amprenavir
Palbociclib {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil
Palbociclib may lead to a major life threatening interaction when taken with Amprenavir
Palbociclib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated